11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.

Journal article

IMPORTANCE OF THE FIELD: The prevalence of obesity and type 2 diabetes is rising and reaching pandemic proportions. For this reason, identification of novel therapeutic targets is urgently needed. AREAS COVERED IN THIS REVIEW: The endoluminal enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) catalyzes glucocorticoid activation in key metabolic tissues including skeletal muscle, liver and adipose tissue, and is strongly implicated in the pathogenesis of obesity, type 2 diabetes a...

Expand abstract

Authors: Morgan, SA; Tomlinson, J

• Publication status: Published
• Journal: Expert opinion on investigational drugs
• Volume: 19
• Issue: 9
• Pages: 1067-1076
• Publication date: 2010-09-01
• DOI: 10.1517/13543784.2010.504713
• EISSN: 1744-7658
• ISSN: 1354-3784
• Language: English
• Keywords: Metabolic Syndrome X; Hypoglycemic Agents; 11-beta-Hydroxysteroid Dehydrogenases; Mice; Adipose Tissue; 11-beta-Hydroxysteroid Dehydrogenase Type 1; Liver; Humans; Obesity; Diabetes Mellitus, Type 2; Lipid Metabolism; Glucocorticoids; Animals; Clinical Trials as Topic; Insulin Resistance